DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,585,493 B2 Hale Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,585,493 B2 Hale Et Al US007585493B2 (12) United States Patent (10) Patent No.: US 7,585,493 B2 Hale et al. (45) Date of Patent: *Sep. 8, 2009 (54) THIN-FILM DRUG DELIVERY ARTICLE AND tion No. 60/336,218, filed on Oct. 30, 2001, provi METHOD OF USE sional application No. 60/335,049, filed on Oct. 30, 2001, provisional application No. 60/345,882, filed on (75) Inventors: Ron L. Hale, Woodside, CA (US); Amy Nov. 9, 2001, provisional application No. 60/345,145, Lu, Los Altos, CA (US); Daniel J. filed on Nov. 9, 2001, provisional application No. Myers, Mountain View, CA (US); 60/345,876, filed on Nov. 9, 2001, provisional appli Joshua D. Rabinowitz, Mountain View, cation No. 60/332,280, filed on Nov. 21, 2001, provi CA (US); Martin J. Wensley, San sional application No. 60/332.279, filed on Nov. 21, Francisco, CA (US) 2001, provisional application No. 60/332,165, filed on Nov. 21, 2001, provisional application No. 60/342, (73) Assignee: Alexza Pharmaceuticals, Inc., 066, filed on Dec. 18, 2001, provisional application Mountain View, CA (US) No. 60/371,457, filed on Apr. 9, 2002, provisional - application No. 60/412,068, filed on Sep. 18, 2002. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (51) Int. Cl. U.S.C. 154(b) by 995 days. A6IR 9/12 (2006.01) A6IR 9/14 (2006.01) This patent is Subject to a terminal dis- A6M I5/00 (2006.01) claimer. (52) U.S. Cl. ........................... 424/45; 424/46; 424/434; 424/489: 424/499; 514/958: 128/200.14: (21) Appl. No.: 10/633,877 128/200.15; 128/200.24 (22) Filed: Aug. 4, 2003 (58) Field of Classification Search ................... 424/45, 424/46, 489, 499, 434; 514/958: 128/200.14, (65) Prior Publication Data 128/200.24, 203.15 See application file for complete search history. US 2007/OO31340 A1 Feb. 8, 2007 (56) References Cited Related U.S. Application Data U.S. PATENT DOCUMENTS (63) Continuation-in-part of application No. 10/322.227, filed on Dec. 17, 2002, now abandoned, application 1,239,634 A 9, 1917 Stuart No. 10/633,877, which is a continuation-in-part of Continued application No. 10/280,315, filed on Oct. 25, 2002, (Continued) now abandoned, application No. 10/633,877, which is FOREIGN PATENT DOCUMENTS a continuation-in-part of application No. 10/302.614, filed on Nov. 21, 2002, application No. 10/633,877, CA 2152684 1, 1996 which is a continuation-in-part of application No. 10/302,010, filed on Nov. 21, 2002, now Pat. No. (Continued) 7,078,016, application No. 10/633,877, which is a con- OTHER PUBLICATIONS tinuation-in-part of application No. 10/154,594, filed on May 23, 2002, now Pat. No. 6,740,309, application U.S. Appl. No. 10/633,876, filed Aug. 4, 2003, Hale et al. No. 10/633,877, which is a continuation-in-part of (Continued) application No. 10/154,765, filed on May 23, 2002, now Pat. No. 6,814,955, application No. 10/633,877, Primary Examiner Mina Haghighatian which is a continuation-in-part of application No. (74) Attorney, Agent, or Firm—Swanson & Bratschun, 10/155,097, filed on May 23, 2002, now Pat. No. L.L.C. 6,716,417, application No. 10/633,877, which is a con tinuation-in-part of application No. 10/155,373, filed (57) ABSTRACT on May 22, 2002, now Pat. No. 6,737,043, application No. 10/633,877, which is a continuation-in-part of An article for use in an aerosol device, for producing an application No. 10/155,621, filed on May 22, 2002, aerosol of a drug composition is disclosed. The article now Pat. No. 6,759,029, application No. 10/633,877, includes a heat-conductive Substrate having a Surface with a which is a continuation-in-part of application No. selected Surface area, and a drug composition film on the 10/155,703, filed on May 22, 2002, now Pat. No. substrate surface having a selected film thickness of between 6,803,031, application No. 10/633,877, which is a con- 0.05 and 20 um. The film thickness is such that an aerosol tinuation-in-part of application No. 10/155,705, filed formed by vaporizing the drug composition by heating the on May 22, 2002, now Pat. No. 6,805,854, application Substrate and condensing the vaporized compound contains No. 10/633,877, which is a continuation-in-part of 10% or less drug-degradation product and at least 50% of the total amount of drug composition contained in the film. The (Continued) selected substrate surface area is such as to yield an effective (60) Provisional application No. 60/294.203, filed on May human therapeutic dose of the drug aerosol. Also disclosed 24, 2001, provisional application No. 60/296,225, are methods of making and using the article. filed on Jun. 5, 2001, provisional application No. 60/317,479, filed on Sep. 5, 2001, provisional applica 12 Claims, 18 Drawing Sheets US 7,585,493 B2 Page 2 Related U.S. Application Data 2,309,846 2, 1943 Einar 2.469,656 5, 1949 Lienert application No. 10/153,839, filed on May 21, 2002, 2,714,649 8, 1955 Critzer now Pat. No. 6,776,978, application No. 10/633,877, 2,741,812 4, 1956 Andre which is a continuation-in-part of application No. 2,761,055 8, 1956 Ike 10/153.311, filed on May 21, 2002, now Pat. No. 2,887, 106 5, 1959 Robinson 6,884,408, application No. 10/633,877, which is a con 2,898,649 8, 1959 Murray tinuation-in-part of application No. 10/153,831, filed 2.902,484 9, 1959 Horclois 3,043,977 T. 1962 Morowitz on May 21, 2002, now Pat. No. 6,740,308, application 3,080,624 3, 1963 Webber, III No. 10/633,877, which is a continuation-in-part of 3,164,600 1, 1965 Janssen et al. application No. 10/153.313, filed on May 20, 2002, 3,169,095 2, 1965 Thiel et al. now abandoned, application No. 10/633,877, which is 3,200,819 8, 1965 Gilbert a continuation-in-part of application No. 10/153,139, 3,219,533 11, 1965 Mullins filed on May 20, 2002, now Pat. No. 6,814,954, appli 3,282,729 11, 1966 Richardson et al. cation No. 10/633,877, which is a continuation-in-part 3,296,249 1, 1967 Bell of application No. 10/152,652, filed on May 20, 2002, 3,299,185 1, 1967 Oda et al. now Pat. No. 6,740,307, application No. 10/633,877, 3,371,085 2, 1968 Reeder et al. which is a continuation-in-part of application No. 3,393, 197 T. 1968 Pachter 3.433,791 3, 1969 Bentley et al. 10/152,640, filed on May 20, 2002, now Pat. No. 3,560,607 2, 1971 Hartley et al. 6,743,415, application No. 10/633,877, which is a con 3,701,782 10, 1972 Hester tinuation-in-part of application No. 10/152,639, filed 3,749,547 7, 1973 Gregory et al. on May 20, 2002, now Pat. No. 6,716,416, application 3,763,347 10, 1973 Whitaker et al. No. 10/633,877, which is a continuation-in-part of 3,773.995 11, 1973 Pachter et al. application No. 10/150,857, filed on May 17, 2002, 3,831,606 8, 1974 Damani now Pat. No. 6,716,415, application No. 10/633,877, 3,847,650 11, 1974 Gregory et al. which is a continuation-in-part of application No. 10/ 3,864,326 2, 1975 Babington 3,894,040 7, 1975 Buzby, Jr. 150,591, filed on May 17, 2002, now Pat. No. 6,780, 3,909,463 9, 1975 Hartman 400, application No. 10/633,877, which is a continua 3,930,796 1, 1976 Haensel tion-in-part of application No. 10/151,596, filed on 3,943,941 3, 1976 Boyd et al. May 16, 2002, now Pat. No. 6,855,310, application 3,949,743 4, 1976 Shanbrom No. 10/633,877, which is a continuation-in-part of 3,971,377 7, 1976 Damani application No. 10/151,626, filed on May 16, 2002, 3,982,095 9, 1976 Robinson now Pat. No. 6,783,753, application No. 10/633,877, 3,987,052 10, 1976 Hester, Jr. which is a continuation-in-part of application No. 4,008,723 2, 1977 Borthwicket al. 10/150,267, filed on May 16, 2002, now Pat. No. 4,020,379 4, 1977 Manning 4,045,156 8, 1977 Chu et al. 6,797.259, application No. 10/633,877, which is a con 4,079,742 3, 1978 Rainer et al. tinuation-in-part of application No. 10/150.268, filed 4,104,210 8, 1978 Coran et al. on May 15, 2002, now Pat. No. 6,780,399, application 4,121,583 10, 1978 Chen No. 10/633,877, which is a continuation-in-part of 4,141,369 2, 1979 Burruss application No. 10/150,056, filed on May 15, 2002, 4, 160,765 7, 1979 Weinstock now Pat. No. 6,805,853, application No. 10/633,877, 4,166,087 8, 1979 Cline et al. which is a continuation-in-part of application No.
Load more

Recommended publications
  • Fluoxetine Elevates Allopregnanolone in Female Rat Brain but Inhibits A
    British Journal of DOI:10.1111/bph.12891 www.brjpharmacol.org BJP Pharmacology RESEARCH PAPER Correspondence Jonathan P Fry, Department of Neuroscience, Physiology and Pharmacology, University College Fluoxetine elevates London, Gower Street, London WC1E 6BT, UK. E-mail: [email protected] allopregnanolone in female ---------------------------------------------------------------- Received 27 March 2014 rat brain but inhibits a Revised 3 July 2014 Accepted steroid microsomal 18 August 2014 dehydrogenase rather than activating an aldo-keto reductase JPFry1,KYLi1, A J Devall2, S Cockcroft1, J W Honour3,4 and T A Lovick5 1Department of Neuroscience, Physiology and Pharmacology, 4Institute of Women’s Health, University College London (UCL), 3Department of Chemical Pathology, University College London Hospital, London, 2School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, and 5School of Physiology and Pharmacology, University of Bristol, Bristol, UK BACKGROUND AND PURPOSE Fluoxetine, a selective serotonin reuptake inhibitor, elevates brain concentrations of the neuroactive progesterone metabolite allopregnanolone, an effect suggested to underlie its use in the treatment of premenstrual dysphoria. One report showed fluoxetine to activate the aldo-keto reductase (AKR) component of 3α-hydroxysteroid dehydrogenase (3α-HSD), which catalyses production of allopregnanolone from 5α-dihydroprogesterone. However, this action was not observed by others. The present study sought to clarify the site of action for fluoxetine in elevating brain allopregnanolone. EXPERIMENTAL APPROACH Adult male rats and female rats in dioestrus were treated with fluoxetine and their brains assayed for allopregnanolone and its precursors, progesterone and 5α-dihydroprogesterone. Subcellular fractions of rat brain were also used to investigate the actions of fluoxetine on 3α-HSD activity in both the reductive direction, producing allopregnanolone from 5α-dihydroprogesterone, and the reverse oxidative direction.
    [Show full text]
  • The Influence of Membrane Cholesterol on GABAA Currents in A
    The School of Pharmacy University of London THE INFLUENCE OF MEMBRANE CHOLESTEROL ON GABAa c u r r e n t s IN ACUTELY DISSOCIATED RAT HIPPOCAMPAL NEURONES Thongchai Sooksawate B.Sc. in Pharm., M.Sc. Department of Pharmacology, The School of Pharmacy, University of London, 29-39 Brunswick Square, London WCIN lAX UK A thesis submitted for the Degree of Doctor of Philosophy, University of London 1999 ProQuest Number: 10104210 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10104210 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Cholesterol has been shown to act as a modulator of many membrane proteins and this thesis extends these observations to the GABA a receptor. Since the neuroactive steroids are structurally related to cholesterol and are known to modulate the function of the GAB A A receptor, it was hypothesised that membrane cholesterol might interact with the recognition site for neuroactive steroids on the GABA a receptor. Acutely dissociated rat hippocampal neurones were enriched with cholesterol by incubation with either liposomes containing cholesterol or methyl-P-cyclodextrin complexed with cholesterol.
    [Show full text]
  • Comparison of Pregnenolone Sulfate, Pregnanolone and Estradiol Levels
    Rustichelli et al. The Journal of Headache and Pain (2021) 22:13 The Journal of Headache https://doi.org/10.1186/s10194-021-01231-9 and Pain SHORT REPORT Open Access Comparison of pregnenolone sulfate, pregnanolone and estradiol levels between patients with menstrually-related migraine and controls: an exploratory study Cecilia Rustichelli1, Elisa Bellei2, Stefania Bergamini2, Emanuela Monari2, Flavia Lo Castro3, Carlo Baraldi4, Aldo Tomasi2 and Anna Ferrari4* Abstract Background: Neurosteroids affect the balance between neuroexcitation and neuroinhibition but have been little studied in migraine. We compared the serum levels of pregnenolone sulfate, pregnanolone and estradiol in women with menstrually-related migraine and controls and analysed if a correlation existed between the levels of the three hormones and history of migraine and age. Methods: Thirty women (mean age ± SD: 33.5 ± 7.1) with menstrually-related migraine (MM group) and 30 aged- matched controls (mean age ± SD: 30.9 ± 7.9) participated in the exploratory study. Pregnenolone sulfate and pregnanolone serum levels were analysed by liquid chromatography-tandem mass spectrometry, while estradiol levels by enzyme-linked immunosorbent assay. Results: Serum levels of pregnenolone sulfate and pregnanolone were significantly lower in the MM group than in controls (pregnenolone sulfate: P = 0.0328; pregnanolone: P = 0.0271, Student’s t-test), while estradiol levels were similar. In MM group, pregnenolone sulfate serum levels were negatively correlated with history of migraine (R2 = 0.1369; P = 0.0482) and age (R2 = 0.2826, P = 0.0025) while pregnenolone sulfate levels were not age-related in the control group (R2 = 0.04436, P = 0.4337, linear regression analysis).
    [Show full text]
  • Bioanalysis, Biomarker, and Flow Cytometry Assay List
    LABORATORY RESOURCES Bioanalysis, Biomarker, and Flow Cytometry Assay List PRA Laboratories | Solutions for Drug Development Behind every sample waiting to be analyzed, there is a patient waiting to be cured. GLP–Compliant Bioanalytical • Global Supply Logistics • Biomarker Strategic Consultation Laboratories Utilizing the following technologies and facilities: PRA maintains two modern bioanalytical laboratories in Lenexa, Kansas, USA and Assen, Netherlands. Their strategic • Sciex LC/MS/MS, Agilent, and Waters UPLC systems locations near our early phase Clinical Research Units (CRUs) • ELISA, MSD ECLIA, EMD Singulex Erenna, SMCxPro, allow time-critical and limited stability samples to be analyzed ProteinSimple ELLA, qPCR quickly. The laboratories both conduct bioanalysis of small • FACSCanto 8 Color, Fortessa 18 Color Flow Cytometers, molecules, biologics, and biomarkers for pre-clinical and and Glomax Luminescence plate reader Phase I-IV human clinical studies. They are fully harmonized • Hamilton and Tomtec Robotic Automation operations and adhere to the same stringent global regulatory • Radioisotope analysis laboratory, with a permanent license guidelines, including GLP compliance. for the analysis of radiolabeled compounds (14C, 3H) These facilities provide the ideal environment for complex • Biohazard laboratory with a Biosafety Level II license bioanalytical services, including standalone projects, those (microbiological laboratory Class II [ML-II]), qualified to combined with an early phase trial in one of PRA’s CRUs, and handle potentially infected samples those conducted in conjunction with PRA’s Product Registration • Co-located Phase I Clinics at both laboratories Services division. Both laboratories are equipped with the latest technologies and infrastructure, as required by pharmaceutical and biotechnology companies. Full-Service Clinical Laboratory Our Bioanalytical Laboratory services include: PRA also offers clinical chemistry services in a fully equipped, • Pharmacokinetic bioanalysis of small molecules and biologics dedicated laboratory.
    [Show full text]
  • Paul S. García, MD, Phd 2/13/2018 1 EMORY UNIVERSITY SCHOOL OF
    EMORY UNIVERSITY SCHOOL OF MEDICINE STANDARD CURRICULUM VITAE FORMAT Revised: May 23, 2018 1. Name: Paul S. García, MD, PhD 2. Office Address: Atlanta VA Medical Center Room 4A 178 1670 Clairmont Road Decatur, Georgia 30033 Telephone: (404) 321-6111 ext 7570 3. E-mail Address: [email protected] 4. Citizenship: United States of America 5. Current Titles and Affiliations: a. Academic Appointments: i. Primary Appointments: Associate Professor of Anesthesiology, Emory University School of Medicine, 2018 – present (effective September 1, 2018) ii. Secondary Appointments: Associate Co-Director, MD/PhD Program, Emory University School of Medicine, 2017 – present b. Clinical Appointments: Staff Physician, Anesthesiology Service, Atlanta VA Medical Center, 2010 – present Attending Physician, Anesthesiology Department, Emory University Hospital, Emory University Hospital Midtown & Ambulatory Surgery Center, 2010 – present Medical Director, Neuroanesthesia and the Post Anesthesia Care Unit, Anesthesiology Service, Atlanta VA Medical Center, 2015 – present Neuroanesthesia Fellowship Co-Director (Research), Department of Anesthesiology, 2017 – present c. Other Appointments: Program Faculty, Neuroscience, Graduate Division of Biological and Biomedical Sciences, Emory University School of Medicine, 2014 – present Program Faculty, Computational Neuroscience, Graduate Division of Biological and Biomedical Sciences, Emory University School of Medicine, 2015 – present Academic Advisory Board, MD/PhD Program, Emory University School of Medicine, 2016 – present Program Director, Legacy Scholars Program, Emory University School of Medicine, 2017 – present Paul S. García, MD, PhD 2/13/2018 1 Program Faculty, Biomedical Engineering, Georgia Institute of Technology, 2017 – present Affiliate Graduate Faculty, The Graduate School, Virginia Commonwealth University, 2017 – present d. Previous Appointments Assistant Professor of Anesthesiology, Emory University School of Medicine, 2010 – 2018 6.
    [Show full text]
  • ALCOHOL RESEARCH: Current Reviews
    ALCOHOL RESEARCH: Current Reviews Effects of Alcohol Dependence and Withdrawal on Stress Responsiveness and Alcohol Consumption Howard C. Becker, Ph.D. A complex relationship exists between alcohol-drinking behavior and stress. Alcohol Howard C. Becker, Ph.D., has anxiety-reducing properties and can relieve stress, while at the same time acting is a professor of psychiatry as a stressor and activating the body’s stress response systems. In particular, chronic alcohol exposure and withdrawal can profoundly disturb the function of the body’s and neuro science at the neuroendocrine stress response system, the hypothalamic–pituitary–adrenocortical Charleston Alcohol Research (HPA) axis. A hormone, corticotropin-releasing factor (CRF), which is produced and Center, Department of Psychiatry released from the hypothalamus and activates the pituitary in response to stress, plays and Behavioral Sciences, a central role in the relationship between stress and alcohol dependence and Department of Neurosciences, withdrawal. Chronic alcohol exposure and withdrawal lead to changes in CRF activity Medical University of South both within the HPA axis and in extrahypothalamic brain sites. This may mediate the Carolina, and a medical emergence of certain withdrawal symptoms, which in turn influence the susceptibility research career scientist at to relapse. Alcohol-related dysregulation of the HPA axis and altered CRF activity within the Ralph H. Johnson Veterans brain stress–reward circuitry also may play a role in the escalation of alcohol Affairs Medical Center, both in consumption in alcohol-dependent individuals. Numerous mechanisms have been Charleston, South Carolina. suggested to contribute to the relationship between alcohol dependence, stress, and drinking behavior. These include the stress hormones released by the adrenal glands in response to HPA axis activation (i.e., corticosteroids), neuromodulators known as neuroactive steroids, CRF, the neurotransmitter norepinephrine, and other stress- related molecules.
    [Show full text]
  • Behavioral, Physiological, and Neurological Influences of Pheromones and Interomones in Domestic Dogs
    BEHAVIORAL, PHYSIOLOGICAL, AND NEUROLOGICAL INFLUENCES OF PHEROMONES AND INTEROMONES IN DOMESTIC DOGS By Glenna Michelle Pirner, B.S., M.S. A DISSERTATION in ANIMAL SCIENCE Submitted to the Graduate Faculty Of Texas Tech University in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY John J. McGlone, Ph.D. Chairperson of the Committee Alexandra Protopopova, Ph.D. Nathaniel Hall, Ph.D. Arlene Garcia, Ph.D. Yehia Mechref, Ph.D. Mark Sheridan, Ph.D. Dean of the Graduate School May 2018 Texas Tech University, Glenna M. Pirner, May 2018 Copyright 2016, Glenna M. Pirner ACKNOWLEDGEMENTS When I accepted a staff position as a research aide at Texas Tech University, I never dreamed that work would culminate a Ph.D., and I would like to first express my gratitude to Dr. John McGlone for giving me this opportunity. Your patience and guidance have provided me with invaluable knowledge and skills that will remain with me throughout my career. I would also like to thank Dr. Protopopova, Dr. Hall, Dr. Garcia, and Dr. Mechref for taking time to be a part of my committee and provide their feedback and advice. Your insight into each respective field has taught me to broaden my thinking and I look forward to future collaborations. I am deeply appreciative of the undergraduate research assistants and my fellow graduate students both in our lab and the department for their encouragement and support during my years here, especially Guilherme, Matt, Edgar, Lingna, Alexis, Gizell, Adrian, and Garrett. The teamwork and friendship made even the toughest days more bearable, and I wish all of you the best in your future endeavors.
    [Show full text]
  • Downloaded from Bioscientifica.Com at 10/01/2021 09:36:04PM Via Free Access 68 R KANCHEVA and Others
    67 Relationships of circulating pregnanolone isomers and their polar conjugates to the status of sex, menstrual cycle, and pregnancy Radmila Kancheva, Martin Hill, David Cibula1, Helena Vcˇela´kova´, Lyudmila Kancheva, Jana Vrbı´kova´, Toma´sˇ Fait1, Antonı´nParˇ´ızek1 and Luboslav Sta´rka Institute of Endocrinology, Na´rodnı´trˇı´da 8, CZ 116 94 Prague 1, Czech Republic 1Department of Gynecology and Obstetrics, 1st Medical Faculty, Charles University, Apolina´rˇska´ 18, CZ 128 51 Prague 2, Czech Republic (Requests for offprints should be addressed to M Hill; Email: [email protected]) Abstract Pregnanolone isomers (PIs) and their polar conjugates (PICs) found in P indicate the more intensive conjugation of 5a-PI modulate ionotropic receptors such as g-aminobutyric acid during pregnancy. This mechanism probably provides for the or pregnane X receptors. Besides, brain synthesis, PI elimination of neuroinhibitory P3a5a in the maternal penetrates the blood–brain barrier. We evaluated the compartment. Additionally, our result points to a limited physiological importance of PI respecting the status of sex, sulfation capacity for neuroinhibitory P3a5b in P. In contrast menstrual cycle, and pregnancy. Accordingly, circulating to the situation in M, F, and L where the P3a5bC is the most levels of allopregnanolone (P3a5a), isopregnanolone abundant PIC, and P3a5b is present in minor quantities (P3b5a), pregnanolone (P3a5b), epipregnanolone (P3b5b), compared with the P3a5a,P3a5b may acquire physiological their polar conjugates, and related steroids were measured in importance during pregnancy, contributing to the sustaining 15 men (M), 15 women in the follicular phase (F), 16 women thereof. On the other hand, the declining formation of in the luteal phase (L), and 30 women in the 36th week of P3a5b may participate in the initiation of parturition, given gestation (P) using GC–MS.
    [Show full text]
  • Endotoxin Increases Sleep and Brain Allopregnanolone Concentrations in Newborn Lambs
    0031-3998/02/5206-0892 PEDIATRIC RESEARCH Vol. 52, No. 6, 2002 Copyright © 2002 International Pediatric Research Foundation, Inc. Printed in U.S.A. Endotoxin Increases Sleep and Brain Allopregnanolone Concentrations in Newborn Lambs SARAID S. BILLIARDS, DAVID W. WALKER, BENEDICT J. CANNY, AND JONATHAN J. HIRST Department of Physiology, Monash University, Clayton, Victoria, Australia ABSTRACT Infection has been identified as a risk factor for sudden infant LPS-induced increase of allopregnanolone in the brain may death syndrome (SIDS). Synthesis of allopregnanolone, a neu- contribute to somnolence in the newborn, and may be responsible roactive steroid with potent sedative properties, is increased in for the reduced arousal thought to contribute to the risk of SIDS response to stress. In this study, we investigated the effect of in human infants. (Pediatr Res 52: 892–899, 2002) endotoxin (lipopolysaccharide, LPS) on brain and plasma allo- pregnanolone concentrations and behavior in newborn lambs. LPS was given intravenously (0.7 ␮g/kg) at 12 and 15 d of age Abbreviations (n ϭ 7), and resulted in a biphasic febrile response (p Ͻ 0.001), AS, active sleep hypoglycemia, lactic acidemia (p Ͻ 0.05), a reduction in the AW, awake incidence of wakefulness, and increased nonrapid eye movement ECoG, electrocorticogram sleep and drowsiness (p Ͻ 0.05) compared with saline-treated EMG, electromyogram lambs (n ϭ 5). Plasma allopregnanolone and cortisol were EOG, electrooculogram significantly (p Ͻ 0.05) increased after LPS treatment. These GABA, ␥-aminobutyric acid responses to LPS lasted 6–8 h, and were similar at 12 and 15 d GABAA, GABA-A type receptor of age.
    [Show full text]
  • Detectx® Progesterone Metabolites EIA Kit
    NEW PRODUCT PROGESTERONE METABOLITES EIA KIT Use: Measure General Progesterone Metabolites Catalog Number: and Generate Reproductive Profiles K068-H1 (1 Plate Kit) Sample: Fecal Extracts and Urine K068-H5 (5 Plate Kit) Sensitivity: 51.2 pg/mL Time to Answer: 1.5 Hours Samples/Kit: 40 or 232 in Duplicate Stability: Liquid, 4°C Stable Reagents Progesterone (P4, pregn-4-ene-3,20-dione) belongs to a class of hormones called progestogens and is an essential regulator of human femal reproductive function in the uterus, ovary, mamary gland, and brain. It also plays arole in the cardiovascular system. Progestogens are the primary hormones involved in the female menstural cycle, gestation, and embryogenesis of humans and most other species. 100 1.2 90 In different animal species, progesterone 1.0 is metabolized and excreted as a variety 80 of general progesterone by-products. %B/B0 70 Net OD molecules. Common metabolites include 0.8 5-reduced progesterones, pregnanolones, and 60 hydroprogesterones. Measurement of these 50 0.6 general progesterone metabolites provides vital data for studying reproductive and 40 0.4 survival strategies for endangered species. 30 20 0.2 10 0 0.0 100 1000 10000 WWW.ARBORASSAYS.COM DetectX® Progesterone Metabolites EIA Kit The DetectX® Progesterone Metabolite Immunoassay Kit, K068-H1/H5, was developed to quantitatively measure Progesterone metabolites present in extracted fecal samples and urine. This assay provides another valuable tool for profiling progestrone metabolites. The cross-reactivity profile of the newest
    [Show full text]
  • (DHEA) and Pregnanolone with Existing Pharmacotherapies for Alcohol Abuse on Ethanol- and Food-Maintained Responding in Male Rats
    Alcohol 49 (2015) 127e138 Contents lists available at ScienceDirect Alcohol journal homepage: http://www.alcoholjournal.org/ Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats Mary W. Hulin a,b,*, Michelle N. Lawrence a, Russell J. Amato c, Peter F. Weed a, Peter J. Winsauer a,b a Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA b Comprehensive Alcohol Research Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA c Neuroscience Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA article info abstract Article history: The present study compared two putative pharmacotherapies for alcohol abuse and dependence, de- Received 6 June 2014 hydroepiandrosterone (DHEA) and pregnanolone, with two Food and Drug Administration (FDA)- Accepted 1 July 2014 approved pharmacotherapies, naltrexone and acamprosate. Experiment 1 assessed the effects of different doses of DHEA, pregnanolone, naltrexone, and acamprosate on both ethanol- and food- maintained responding under a multiple fixed-ratio (FR)-10 FR-20 schedule, respectively. Experiment Keywords: 2 assessed the effects of different mean intervals of food presentation on responding for ethanol under a Ethanol FR-10 variable-interval (VI) schedule, whereas Experiment 3 assessed the effects of a single dose of each Multiple schedules DHEA drug under a FR-10 VI-80 schedule. In Experiment 1, all four drugs dose-dependently decreased response Pregnanolone rate for both food and ethanol, although differences in the rate-decreasing effects were apparent among Naltrexone the drugs.
    [Show full text]
  • (Progesterone, USP), 100 Mg and 200 Mg WARNING
    Progesterone Capsules (progesterone, USP), 100 mg and 200 mg A. Absorption After oral administration of progesterone as a soft-gelatin capsule formulation, WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER and maximum serum concentrations were attained within 3 hours. The absolute PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN bioavailability of progesterone is not known. Table 1 summarizes the mean THERAPY pharmacokinetic parameters in postmenopausal women after five oral daily doses of progesterone capsules 100 mg as a soft-gelatin capsule formulation. Cardiovascular Disorders and Probable Dementia TABLE 1. Pharmacokinetic Parameters of Progesterone Capsules Estrogens plus progestin therapy should not be used for the prevention of Progesterone Capsules Daily Dose cardiovascular disease or dementia (see CLINICAL STUDIES and Parameter 100 mg 200 mg 300 mg WARNINGS, Cardiovascular disorders and Probable dementia). Cmax (ng/mL) 17.3 ± 21.9 a 38.1 ± 37.8 60.6 ± 72.5 The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis, pulmonary embolism, stroke and Tmax (hr) 1.5 ± 0.8 2.3 ± 1.4 1.7 ± 0.6 myocardial infarction in postmenopausal women (50 to 79 years of age) during AUC (ng × hr/mL) 175.7 ± (0-10) 43.3 ± 30.8 101.2 ± 66 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] 170.3 combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to a Mean ± S.D. placebo (see CLINICAL STUDIES and WARNINGS, Cardiovascular disorders). Serum progesterone concentrations appeared linear and dose proportional following multiple dose administration of progesterone capsules 100 mg over the The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of dose range 100 mg per day to 300 mg per day in postmenopausal women.
    [Show full text]